Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dipyridamole
Drug ID BADD_D00692
Description A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Indications and Usage For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
Marketing Status approved
ATC Code B01AC07
DrugBank ID DB00975
KEGG ID D00302
MeSH ID D004176
PubChem ID 3108
TTD Drug ID D0F9GE
NDC Product Code 0641-2569; 65015-782; 65404-005; 66039-917; 68382-187; 0527-1463; 71205-895; 0115-1070; 0115-1071; 0115-1072; 51407-627; 62559-237; 69584-183; 0527-1461; 51407-626; 65841-662; 62559-236; 64980-133; 65841-663; 65841-664; 69584-182; 51407-628; 51662-1447; 0404-9852; 62559-235; 68382-188; 69584-181; 17511-122; 64980-134; 51927-1571; 68166-003; 71205-894; 71205-896; 64980-135; 68382-189; 0527-1462; 12660-0084
UNII 64ALC7F90C
Synonyms Dipyridamole | Dipyramidole | Apo-Dipyridamole | Apo Dipyridamole | Cerebrovase | Persantine | Persantin | Curantil | Curantyl | Kurantil | Miosen | Novo-Dipiradol | Novo Dipiradol | Antistenocardin | Cléridium
Chemical Information
Molecular Formula C24H40N8O4
CAS Registry Number 58-32-2
SMILES C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemorrhagic stroke17.08.01.011; 24.07.04.014--Not Available
Head discomfort17.02.05.027--Not Available
Headache17.14.01.0010.007614%
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.004--Not Available
Hydrocephalus17.07.01.0010.000976%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.000976%
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperventilation19.01.02.004; 22.02.01.006--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypotension24.06.03.0020.001464%
Hypoxia22.02.02.003--
Immune system disorder10.02.01.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction08.02.03.014; 12.07.03.015--
Intermittent claudication24.04.03.001--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Laryngospasm22.04.02.002--
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Menopausal symptoms21.02.02.002--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Muscle spasms15.05.03.004--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.0080.000976%Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages